Back

SGLT2 inhibitor treatment in patients with cardiac amyloidosis

13 May 2024 (16:17 - 16:25)
Organised by: Logo
Congress Presentation Part of: Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Daniel Lavall

University Hospital Leipzig, Leipzig (Germany)

6 More presentations in this session

Presentation thumbnail
International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction
Doctor S. Yun Viladomat (Hospitalet De Llobregat, ES)
Abstract Slides Video
Presentation thumbnail
Age- and sex-related trends in transthyretin amyloid cardiomyopathy prevalence in older patients with unexplained hypertrophic cardiomyopathy
Professor R. Barriales-Villa (Coruna, A, ES)
Abstract Slides Video
Presentation thumbnail
Prognostic importance of the 6-minute walk test in transthyretin cardiac amyloidosis
Doctor A. Ioannou (Greater London, GB)
Abstract Slides Video
Presentation thumbnail
Diverse presentations of transthyretin cardiac amyloidosis beyond heart failure with preserved ejection fraction
Miss A. Achten (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Cardiac manifestations as precursors to ATTR amyloidosis diagnosis: results from the multi-country OverTTuRe study
Doctor K. Jarbrink (Gothenburg, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment
Video

The Event

Event poster

Heart Failure 2024

13 May 2024 16:17 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2 inhibitors in patients with amyloidosis and heart failure: a worldwide retrospective cohort study
31 August 2024
thumbnail
Congress Presentation
Potential hematopoietic effects of SGLT2 inhibitors in patients with cardiac amyloidosis.
30 August 2024
thumbnail
Congress Presentation
New horizons in transthyretin cardiac amyloidosis therapy: A systematic review and meta-analysis of sodium-glucose cotransporter 2 inhibitors efficacy
31 August 2025
thumbnail
Congress Presentation
Short-term effects of SGLT2 inhibitors on myocardial extracellular volume, left ventricular function and inflammation in patients with HFpEF and diabetes mellitus
29 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources